

Publications PubMed=833871; DOI=10.1093/jnci/58.2.209 Fogh J., Wright W.C., Loveless J.D. Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J. Natl. Cancer Inst. 58:209-214(1977)

PubMed=450131; DOI=10.1038/279797a0 Day R.S. III, Ziolkowski C.H.J. Human brain tumour cell strains with deficient host-cell reactivation of N-methyl-N'-nitro-N-nitrosoguanidine-damaged adenovirus 5. Nature 279:797-799(1979)

PubMed=22282976; DOI=10.1093/carcin/1.1.21 Day R.S. III, Ziolkowski C.H.J., Scudiero D.A., Meyer S.A., Mattern M.R. Human tumor cell strains defective in the repair of alkylation damage. Carcinogenesis 1:21-32(1980)

PubMed=6260907; DOI=10.1097/00005072-198105000-00001 Bigner D.D., Bigner S.H., Ponten J., Westermarck B., Mahaley M.S. Jr., Ruoslahti E., Herschman H., Eng L.F., Wikstrand C.J. Heterogeneity of genotypic and phenotypic characteristics of fifteen permanent cell lines derived from human gliomas. J. Neuropathol. Exp. Neurol. 40:201-229(1981)

PubMed=6220172 Dracopoli N.C., Fogh J. Polymorphic enzyme analysis of cultured human tumor cell lines. J. Natl. Cancer Inst. 70:469-476(1983)

PubMed=6582512; DOI=10.1073/pnas.81.2.568 Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O. Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies. Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984)

PubMed=3518877; DOI=10.3109/07357908609038260 Fogh J. Human tumor lines for cancer research. Cancer Invest. 4:157-184(1986)

PubMed=2253244 Bigner S.H., Humphrey P.A., Wong A.J., Vogelstein B., Mark J., Friedman H.S., Bigner D.D. Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. Cancer Res. 50:8017-8022(1990)

PubMed=8858520; DOI=10.1007/BF00182138 Liang B.C. Effects of hypoxia on drug resistance phenotype and genotype in human glioma cell lines. J. Neurooncol. 29:149-155(1996)

PubMed=9220028; DOI=10.1016/S0303-7207(97)00080-4 Sharif T.R., Luo W., Sharif M. Functional expression of bombesin receptor in most adult and pediatric human glioblastoma cell lines; role in mitogenesis and in stimulating the mitogen-activated protein kinase pathway. Mol. Cell. Endocrinol. 130:119-130(1997)

PubMed=9230885; DOI=10.1093/jnci/89.14.1036 Gomez-Manzano C., Fueyo J., Kyritsis A.P., McDonnell T.J., Steck P.A., Levin V.A., Yung W.K.A. Characterization of p53 and p21 functional interactions in glioma cells en route to apoptosis. J. Natl. Cancer Inst. 89:1036-1044(1997)

PubMed=9842975; DOI=10.1002/(sici)1097-0215(19981218)79:6<640::aid-ijc15>3.0.co;2-z Weller M., Rieger J., Grimm C., Van Meir E.G., De Tribolet N., Krajewski S., Reed J.C., von Deimling A., Dichgans J. Predicting chemoresistance in human malignant glioma cells: the role of molecular genetic analyses. Int. J. Cancer 79:640-644(1998)

PubMed=10074188; DOI=10.1128/JVI.73.4.3338-3350.1999 Arbour N., Cote G., Lachance C., Tardieu M., Cashman N.R., Talbot P.J. Acute and persistent infection of human neural cell lines by human coronavirus OC43. J. Virol. 73:3338-3350(1999)

PubMed=10416987; DOI=10.1111/j.1750-3639.1999.tb00536.x Ishii N., Maier D., Merlo A., Tada M.,

Sawamura Y., Diserens A.-C., Van Meir E.G. Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. *Brain Pathol.* 9:469-479(1999)

PubMed=11351043; DOI=10.1038/labinvest.3780280 Hui A.B.-Y., Lo K.-W., Yin X.-L., Poon W.-S., Ng H.-K. Detection of multiple gene amplifications in glioblastoma multiforme using array-based comparative genomic hybridization. *Lab. Invest.* 81:717-723(2001)

PubMed=11414198; DOI=10.1007/s004320000207 Lahm H., Andre S., Hoeflich A., Fischer J.R., Sordat B., Kaltner H., Wolf E., Gabius H.J. Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures. *J. Cancer Res. Clin. Oncol.* 127:375-386(2001)

PubMed=14614447; DOI=10.1038/sj.onc.1207198 Wischhusen J., Naumann U., Ohgaki H., Rastinejad F., Weller M. CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death. *Oncogene* 22:8233-8245(2003)

PubMed=14655754; DOI=10.1111/j.1750-3639.2003.tb00479.x Bahr O., Rieger J., Duffner F., Meyermann R., Weller M., Wick W. P-glycoprotein and multidrug resistance-associated protein mediate specific patterns of multidrug resistance in malignant glioma cell lines, but not in primary glioma cells. *Brain Pathol.* 13:482-494(2003)

PubMed=16232199; DOI=10.1111/j.1349-7006.2005.00099.x Saigusa K., Hashimoto N., Tsuda H., Yokoi S., Maruno M., Yoshimine T., Aoyagi M., Ohno K., Imoto I., Inazawa J. Overexpressed Skp2 within 5p amplification detected by array-based comparative genomic hybridization is associated with poor prognosis of glioblastomas. *Cancer Sci.* 96:676-683(2005)

PubMed=16697959; DOI=10.1016/j.ccr.2006.03.030 Lee J., Kotliarova S., Kotliarov Y., Li A., Su Q., Donin N.M., Pastorino S., Purow B.W., Christopher N., Zhang W., Park J.K., Fine H.A. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. *Cancer Cell* 9:391-403(2006)

PubMed=17595512; DOI=10.1159/000104150 Rieger J., Frank B., Weller M., Wick W. Mechanisms of resistance of human glioma cells to Apo2 ligand/TNF-related apoptosis-inducing ligand. *Cell. Physiol. Biochem.* 20:23-34(2007)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458 Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A. A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers. *Cancer Res.* 70:2158-2164(2010)

PubMed=20593219; DOI=10.1007/s11060-010-0283-9 Blough M.D., Beauchamp D.C., Westgate M.R., Kelly J.J.P., Cairncross J.G. Effect of aberrant p53 function on temozolomide sensitivity of glioma cell lines and brain tumor initiating cells from glioblastoma. *J. Neurooncol.* 102:1-7(2011)

PubMed=21406405; DOI=10.1158/0008-5472.CAN-10-3112 Grzmil M., Morin P. Jr., Lino M.M., Merlo A., Frank S., Wang Y., Moncayo G., Hemmings B.A. MAP kinase-interacting kinase 1 regulates SMAD2-dependent TGF-beta signaling pathway in human glioblastoma. *Cancer Res.* 71:2392-2402(2011)

PubMed=22570425; DOI=10.1093/neuonc/nos072 Bady P., Diserens A.-C., Castella V., Kalt S., Heinemann K., Hamou M.-F., Delorenzi M., Hegi M.E. DNA fingerprinting of glioma cell lines and considerations on similarity measurements. *Neuro-oncol.* 14:701-711(2012)

PubMed=26496030; DOI=10.18632/oncotarget.6171 Patil V., Pal J., Somasundaram K. Elucidating the cancer-specific genetic alteration spectrum of glioblastoma derived cell lines from whole exome and RNA sequencing. Oncotarget 6:43452-43471(2015)

From:

<https://neurosurgerywiki.com/wiki/> - **Neurosurgery Wiki**

Permanent link:

<https://neurosurgerywiki.com/wiki/doku.php?id=u373>

Last update: **2024/06/07 02:56**

